China’s Top Regulator Upholds Tough Stance Against 'Redundant' Clinical Trials

PD-1 Overcrowding A Growing Issue

 
• By Dexter Jie Yan

China's Center for Drug Evaluation has issued fresh warnings that it will tighten reviews of anti-tumor drugs on the grounds that “redundant” development activities waste clinical resources.

clinical trial progress
Chinese regulator vows to continuously raise review requirements to prevent drain on clinical resources. • Source: Alamy

More from China

More from Asia